Identification of abuse and dependence cases through a hospital database

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 12, 2012, Pages 1344-1349

  Daveluy, A ^a,b,c   Miremont Salame G ^a,b,c   Kostrzewa, A ^c   Couret, A ^c   Lacoin, L ^c   Lecomte, C ^c   Moore, N ^a,b,c   Gilleron, V ^c   Haramburu, F ^a,b,c  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSERM   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

Benzodiazepines; Buprenorphine; Computerized; Marijuana abuse; Medical records systems; Patient admission; Pharmacoepidemiology; Substance related disorders

Indexed keywords

AMPHETAMINE; BENZODIAZEPINE; BUPRENORPHINE; CANNABIS; CODEINE; DIAMORPHINE; MORPHINE; TRAMADOL;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CROSS-SECTIONAL STUDY; DATA BASE; DRUG DEPENDENCE; FEMALE; FRANCE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE DRUG ABUSE; PILOT STUDY; PRIORITY JOURNAL; TEACHING HOSPITAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; FRANCE; HOSPITALS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MIDDLE AGED; SUBSTANCE-RELATED DISORDERS;

EID: 84870709934     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3369     Document Type: Article

References (34)

1. Moise P. Organization for economic co-operation and development. Using hospital administrative databases for a disease-based approach to studying health care systems, Aug 2001. http://www.oecd.org/dataoecd/28/10/1889879.pdf [31 May 2012].
2. Aylin P, Bottle A, Majeed A. Use of administrative data or clinical databases as predictors of risk of death in hospital: comparison of models. BMJ 2007; 334: 1044. DOI: 10.1136/bmj.39168.496366.55.
3. van der Hooft CS, Sturkenboom MCJM, van Grootheest K, et al. Adverse drug reaction-related hospitalisations: a nationwide study in The Netherlands. Drug Saf 2006; 29: 161-168.
4. Elalamy I, Le Gal G, Nachit-Ouinekh F, et al. Heparin-induced thrombocytopenia: an estimate of the average cost in the hospital setting in France. Clin Appl Thromb Hemost 2009; 15: 428-434. DOI: 10.1177/1076029608319441.
5. Weill A, Païta M, Tuppin P, et al. Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus. Pharmacoepidemiol Drug Saf 2010; 19: 1256-1262. DOI: 10.1002/pds.2044.
6. Lugardon S, Desboeuf K, Fernet P, et al. Using a capture-recapture method to assess the frequency of adverse drug reactions in a French university hospital. Br J Clin Pharmacol 2006; 62: 225-231. DOI: 10.1111/j.1365-2125.2006.02633.x.
7. Couffignal AL, Lapeyre-Mestre M, Bonhomme C, et al. Adverse effects of anticancer drugs: apropos of a pharmacovigilance study at a specialized oncology institution. Therapie 2000; 55: 635-641.
8. Jouanjus E, Leymarie F, Tubery M, et al. Cannabis-related hospitalizations: unexpected serious events identified through hospital databases. Br J Clin Pharmacol 2011; 71: 758-65. DOI: 10.1111/j.1365-2125.2010.03897.x.
9. Jouanjus E, Pourcel L, Saivin S et al. Use of multiple sources and capture-recapture method to estimate the frequency of hospitalizations related to drug abuse. Pharmacoepidemiol Drug Saf 2012; 21: 733-741. DOI: 10.1002/pds.3280.
10. Baumevieille M, Miremont G, Haramburu F, et al. The French system of evaluation of dependence: establishment in a legal system. Therapie 2001; 56: 15-22.
11. Micallef J, Jolliet P, Victorri-Vigneau C, et al. First meeting of the French CEIP (centres d'évaluation et d'information sur la pharmacodépendance). Assessment of the abuse and pharmacodependence potential during drug development. Therapie 2008; 63: 55-65. DOI: 10.2515/therapie:2008014.
12. Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006; 29: 385-396.
13. Bégaud B, Martin K, Haramburu F, et al. Rates of spontaneous reporting of adverse drug reactions in France. JAMA 2002; 288: 1588. DOI: 10.1001/pubs.JAMA-ISSN-0098-7484-288-13-jlt1002.
14. Moride Y, Haramburu F, Requejo AA et al. Under-reporting of adverse drug reactions in general practice. Br J Clin Pharmacol 1997; 43: 177-181.
15. Baumevieille M, Haramburu F, Bégaud B. Abuse of prescription medicines in southwestern France. Ann Pharmacother 1997; 31: 847-850.
16. World Health Organization. International statistical classification of diseases and related health problems (10th rev). World Health Organization: Geneva, 2007.
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn-text rev). American Psychiatric Association: Washington, DC, 2000.
18. Nordmann S, Frauger E, Pauly V, et al. Misuse of buprenorphine maintenance treatment since introduction of its generic forms: OPPIDUM survey. Pharmacoepidemiol Drug Saf 2012; 21: 184-90. DOI: 10.1002/pds.2263.
19. Afssaps. Centres d'Evaluation et d'Information sur la Pharmacodépendance. OPPIDUM (observatoire des produits Psychotropes illicites ou détournés de leur utilisation médicamenteuse). Résultats de l'enquête 2009. www.ansm.sante.fr/var/ansm_site/storage/original/application/6eaa9d57c265a8278ad1fe55e1bd95f6.pdf [31 May 2012].
20. Barrau K, Thirion X, Micallef J, et al. Comparison of methadone and high dosage buprenorphine users in French care centres. Addiction 2001; 96: 1433-1441. DOI: 10.1046/j.1360-0443.2001.961014337.x.
21. Verdoux H, Bégaud B. Le bon usage des médicaments psychotropes. Office parlementaire d'évaluation des politiques de santé. Assemblée Nationale n°3187, Sénat n°422, 2006.
22. Haute Autorité de Santé. Modalités d'arrêt des benzodiazépines et médicaments apparentés chez le patient âgé. HAS, 2007. http://www.has-sante.fr/portail/jcms/c_601507/arret-des-bzd-recommandations [31 May 2012].
23. INCB. The 2006 Annual Report of the International Narcotics Control Board. United Nation: New York, 2007.
24. INCB. The 2009 Annual Report of the International Narcotics Control Board. United Nation: New York, 2010.
25. Hernandez SH, Nelson LS. Prescription drug abuse: insight into the epidemic. Clin Pharmacol Ther 2010; 88: 307-17. DOI: 10.1038/clpt.2010.154.
26. Centres for Diseases Control and Prevention (CDC). Vital signs: overdoses of prescription opioid pain relievers. United States, 1999-2008. MMWR 2011; 60: 1487-1492.
27. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). 2010 annual report on the state of the drugs problem in Europe. EMCDDA, Lisbon, 2010. http://www.emcdda.europa.eu/publications/annual-report/2010 [31 May 2012].
28. Disdier P, Granel B, Serratrice J, et al. Cannabis arteritis revisited--ten new case reports. Angiology 2001; 52: 1-5. DOI: 10.1177/000331970105200101.
29. Verdoux H, Tournier M. Cannabis use and risk of psychosis: an etiological link? Epidemiol Psichiatr Soc 2004; 13: 113-119.
30. Boeuf O, Lapeyre-Mestre M. Survey of forged prescriptions to investigate risk of psychoactive medications abuse in France: results of OSIAP survey. Drug Saf 2007; 30: 265-276.
31. Djezzar S, Questel F, Burin E, et al. Chemical submission: results of 4-year French inquiry. Int J Legal Med 2009; 123: 213-219. DOI: 10.1007/s00414-008-0291-x.
32. Pradel V, Thirion X, Ronfle E, et al. Assessment of doctor-shopping for high dosage buprenorphine maintenance treatment in a French region: development of a new method for prescription database. Pharmacoepidemiol Drug Saf 2004; 13: 473-481. DOI: 10.1002/pds.892.
33. Micallef J, Pradel V, Thirion X, et al. Use of the health insurance database by the centres for evaluation and information on pharmacodependance: examples, interests and future prospects. Therapie 2004; 59: 581-588.
34. Centre d'épidémiologie sur les causes médicales de décès (CépiDc). Inserm. http://www.cepidc.vesinet.inserm.fr/index.html [31 May 2012].